封面
市場調查報告書
商品編碼
1452434

胰島素幫浦市場- 分產品[設備(管式/繫繩式、無管式)、配件(電池、胰島素儲器或藥筒、胰島素套件插入裝置)]、最終用途(家庭護理、醫院和診所) -全球預測,2024 年- 2032 年

Insulin Pump Market - By Product [Devices (Tubed/tethered, Tubeless), Accessories (Battery, Insulin Reservoir or Cartridges, Insulin Set Insertion Devices)], End-use (Home Care, Hospitals & Clinics) - Global Forecast, 2024 - 2032

出版日期: | 出版商: Global Market Insights Inc. | 英文 120 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

在糖尿病盛行率不斷上升、胰島素幫浦設備技術進步以及人們對連續血糖監測 (CGM) 系統優勢的認知不斷提高的推動下,全球胰島素幫浦市場預計 2024 年至 2032 年CAGR將達到12.4% 。

根據 IDF 預測,到 2045 年,每 8 名成年人中就有 1 人(即約 7.83 億人)患有糖尿病,增幅達 46%。隨著糖尿病成為全球流行病,對能夠更好地管理和控制血糖水平的創新解決方案的需求不斷成長。與傳統的胰島素注射相比,胰島素幫浦為患者提供了更大的靈活性、精確性和便利性,從而推動了胰島素幫浦的採用。此外,與 CGM 系統整合、改進的連接功能以及閉迴路系統的開發等技術進步正在進一步推動產業成長。

整個胰島素幫浦產業根據產品、配件、最終用途和地區進行分類。

由於配件在增強胰島素幫浦設備的功能和可用性方面的作用,預計到 2032 年配件市場將大幅成長。輸液器、儲液器和輸注部位黏合劑等配件是確保高效率、可靠地輸送胰島素的重要組成部分。隨著胰島素幫浦療法的採用不斷增加,對相容配件的需求也增加。此外,製造商正致力於開發具有先進功能的配件,例如延長佩戴時間、提高舒適度和增強連接性,以滿足患者不斷變化的需求。

由於最終用途領域的醫院和診所在胰島素幫浦療法的採用和利用中發揮的作用,它們有望在預測期內快速成長。醫院通常作為胰島素幫浦設備和配件的通路,為患者提供教育、培訓和持續的臨床支援。此外,隨著糖尿病盛行率的不斷上升以及對先進糖尿病管理解決方案的需求不斷增加,預計該細分市場將進一步成長。

在糖尿病盛行率上升、快速城市化和醫療基礎設施改善的推動下,亞太地區胰島素幫浦市場預計到 2032 年將獲得成長。中國和印度等糖尿病人口眾多的國家為產品的採用提供了巨大的機會。可支配收入的增加、糖尿病管理意識的提高以及政府改善醫療保健機會的舉措正在進一步推動該地區的市場成長。

目錄

第 1 章:方法與範圍

第 2 章:執行摘要

第 3 章:產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 糖尿病盛行率上升
      • 胰島素幫浦的技術進步
      • 優惠的設備保險和報銷政策
    • 產業陷阱與挑戰
      • 胰島素幫浦成本高
      • 嚴格的政府法規
  • 成長潛力分析
  • 監管環境
  • 技術景觀
  • 波特的分析
  • PESTEL分析
  • 報銷場景
  • 未來市場趨勢
  • 缺口分析

第 4 章:競爭格局

  • 介紹
  • 公司矩陣分析
  • 公司市佔率分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章:市場估計與預測:按產品分類,2018 年 - 2032 年

  • 主要趨勢
  • 裝置
    • 管狀/繫繩
    • 無內胎
  • 配件
    • 電池
    • 胰島素儲液器或藥筒
    • 胰島素套件插入裝置

第 6 章:市場估計與預測:依最終用途,2018 年 - 2032 年

  • 主要趨勢
  • 居家護理
  • 醫院和診所
  • 其他最終用戶

第 7 章:市場估計與預測:按地區分類,2018 年 - 2032 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 8 章:公司簡介

  • Debiotech S.A.
  • F. Hoffmann La Roche AG
  • Insulet Corporation
  • Lenomed Medical
  • Medtronic plc
  • MicroPort Scientific Corporation
  • Nipro Corporation
  • Tandem Diabetic Care Inc.
  • Terumo Corporation
  • ViCentra B.V.
  • Ypsomed
簡介目錄
Product Code: 7983

Global Insulin Pump Market is anticipated to record a CAGR of 12.4% from 2024 to 2032, driven by increasing prevalence of diabetes, technological advancements in insulin pump devices, and growing awareness about the benefits of continuous glucose monitoring (CGM) systems.

According to IDF, by 2045, projections indicate that 1 in 8 adults, or approximately 783 million people, will have diabetes, marking a 46% increase. With diabetes becoming a global epidemic, there is a growing demand for innovative solutions that offer better management and control of blood sugar levels. Insulin pumps offer patients greater flexibility, precision, and convenience in insulin delivery compared to traditional insulin injections, thus driving their adoption. Additionally, technological advancements such as integration with CGM systems, improved connectivity features, and the development of closed-loop systems are further fueling industry growth.

The overall insulin pump industry is classified based on product, accessories, end-use, and region.

Accessories segment is anticipated to grow substantially till 2032, owing to their role in enhancing the functionality and usability of insulin pump devices. Accessories such as infusion sets, reservoirs, and infusion site adhesives are essential components that ensure the efficient and reliable delivery of insulin. As the adoption of insulin pump therapy continues to rise, the demand for compatible accessories is also increasing. Moreover, manufacturers are focusing on developing accessories with advanced features such as extended wear time, improved comfort, and enhanced connectivity to meet the evolving needs of patients.

Hospitals & clinics from end-use segment is poised to grow rapidly during the forecast period, owing to their role in the adoption and utilization of insulin pump therapy. Hospitals often serve as distribution channels for insulin pump devices and accessories, providing patients with education, training, and ongoing clinical support. Moreover, with the growing prevalence of diabetes and the rising demand for advanced diabetes management solutions, further segment growth is anticipated.

Asia Pacific insulin pump market is set to gain traction till 2032, driven by increasing prevalence of diabetes, rapid urbanization, and improving healthcare infrastructure. Countries like China and India, with large diabetic populations, present significant opportunities for product adoption. Rising disposable incomes, increasing awareness about diabetes management, and government initiatives to improve healthcare access are further driving market growth in the region.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of diabetes
      • 3.2.1.2 Technological advancements in insulin pumps
      • 3.2.1.3 Favourable device insurance and reimbursement policies
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of insulin pumps
      • 3.2.2.2 Stringent government regulations
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Porter's analysis
    • 3.6.1 Supplier power
    • 3.6.2 Buyer power
    • 3.6.3 Threat of new entrants
    • 3.6.4 Threat of substitutes
    • 3.6.5 Industry rivalry
  • 3.7 PESTEL analysis
  • 3.8 Reimbursement scenario
  • 3.9 Future market trends
  • 3.10 Gap analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates And Forecast, By Product, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Devices
    • 5.2.1 Tubed/tethered
    • 5.2.2 Tubeless
  • 5.3 Accessories
    • 5.3.1 Battery
    • 5.3.2 Insulin reservoir or cartridges
    • 5.3.3 Insulin set insertion devices

Chapter 6 Market Estimates And Forecast, By End-Use, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Home care
  • 6.3 Hospitals & clinics
  • 6.4 Other end-users

Chapter 7 Market Estimates And Forecast, By Region, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 France
    • 7.3.4 Italy
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 South Korea
    • 7.4.6 Rest of Asia Pacific
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Mexico
    • 7.5.3 Argentina
    • 7.5.4 Rest of Latin America
  • 7.6 Middle East and Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 South Africa
    • 7.6.3 UAE
    • 7.6.4 Rest of Middle East and Africa

Chapter 8 Company Profiles

  • 8.1 Debiotech S.A.
  • 8.2 F. Hoffmann La Roche AG
  • 8.3 Insulet Corporation
  • 8.4 Lenomed Medical
  • 8.5 Medtronic plc
  • 8.6 MicroPort Scientific Corporation
  • 8.7 Nipro Corporation
  • 8.8 Tandem Diabetic Care Inc.
  • 8.9 Terumo Corporation
  • 8.10 ViCentra B.V.
  • 8.11 Ypsomed